GO:0006065 UDP-glucuronate biosynthetic process: Nucleotide Sugar Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006065 describes the set of biochemical reactions that build UDP-glucuronate, a nucleotide sugar formed from glucuronic acid linked to uridine diphosphate.
• UDP-glucuronate is a central branch-point metabolite in the liver, feeding glucuronidation, vitamin C synthesis in some species, and glycosaminoglycan production.
• The pathway is dysregulated in metabolic liver disease: UDP-glucuronate accumulation drives RIPK1-dependent liver damage in nonalcoholic steatohepatitis.
• UGDH, the enzyme that converts UDP-glucose to UDP-glucuronate, is mutated in human developmental disease and is implicated in tumor immune evasion in hepatocellular carcinoma.
• Enzymes downstream of UDP-glucuronate, including UDP-glucuronate decarboxylase and glucuronosyltransferases, control pigment, matrix and signaling outputs in plants and animals.
• CRISPR knockout, point-mutation, knock-in and overexpression models are the standard tools for dissecting causal roles of UDP-glucuronate biosynthetic genes.
Description
UDP-glucuronate biosynthetic process (GO:0006065) is the biological process that produces UDP-glucuronate, a nucleotide sugar composed of glucuronic acid in glycosidic linkage with uridine diphosphate. In humans, the liver is the principal site of this chemistry, where UDP-glucuronate sits at the intersection of glucose metabolism, detoxification and extracellular matrix biosynthesis. The pathway is therefore not a peripheral housekeeping route but a metabolic hub whose output influences drug clearance, hormone balance and structural glycan assembly. Researchers study GO:0006065 because its intermediates and enzymes are increasingly linked to human disease. In nonalcoholic steatohepatitis, altered UDP-glucuronate metabolism controls RIPK1-driven liver damage, placing this nucleotide sugar directly in a cell-death signaling pathway. In hepatocellular carcinoma, UDP-glucuronate decarboxylase 1 promotes tumor immune evasion by accelerating KMT2D loss, connecting the pathway to epigenetic regulation and antitumor immunity. Beyond cancer, mutations in UGDH cause human developmental disease, and the same enzyme family supports hyaluronan and glycosaminoglycan production in connective tissues. Because the pathway is conserved and enzymatically tractable, it is an attractive target for functional genomics. This article summarizes the QuickGO definition, the enzymatic steps, the key genes, the disease links and the CRISPR-based methods used to interrogate UDP-glucuronate biosynthetic process.
UDP-glucuronate biosynthetic process At A Glance
| GO ID | GO:0006065 |
|---|---|
| GO term | UDP-glucuronate biosynthetic process |
| Ontology | biological_process |
| Synonym | UDP-glucuronate anabolism; UDP-glucuronate biosynthesis; UDP-glucuronate formation; UDP-glucuronate synthesis |
| Definition | The chemical reactions and pathways resulting in the formation of UDP-glucuronate, a substance composed of glucuronic acid in glycosidic linkage with uridine diphosphate. |
| Major function | Production of the nucleotide sugar UDP-glucuronate for glucuronidation, vitamin C synthesis in some species, and glycosaminoglycan biosynthesis. |
| Key enzyme | UGDH (UDP-glucose 6-dehydrogenase) catalyzes the oxidation of UDP-glucose to UDP-glucuronate. |
| Downstream enzymes | UDP-glucuronate decarboxylase and glucuronosyltransferases consume UDP-glucuronate for xylose, ascorbate or glucuronide formation. |
| Disease relevance | Nonalcoholic steatohepatitis, hepatocellular carcinoma and UGDH-related developmental disease. |
What Is GO:0006065?
In plain terms, GO:0006065 is the collection of chemical reactions and pathways that result in the formation of UDP-glucuronate, a substance composed of glucuronic acid in glycosidic linkage with uridine diphosphate. The term covers the anabolic route from precursor nucleotide sugars, principally UDP-glucose, to the mature UDP-glucuronate molecule, and it is annotated as a biological process in the Gene Ontology. Its synonyms include UDP-glucuronate anabolism, UDP-glucuronate biosynthesis, UDP-glucuronate formation and UDP-glucuronate synthesis. The process is distinct from downstream catabolic or transfer reactions that consume UDP-glucuronate, such as glucuronidation or decarboxylation, although those reactions are often studied together because they share the same metabolite pool.
Why Is UDP-glucuronate biosynthetic process Important in Cell Biology?
UDP-glucuronate biosynthetic process matters because it supplies a metabolite that is used across diverse physiological systems, from hepatic detoxification and glucose handling to the assembly of hyaluronan and other glycosaminoglycans. Because the pathway is a branch point, its flux can be redirected toward disease-relevant outputs, as shown by the finding that UDP-glucuronate metabolism controls RIPK1-driven liver damage in nonalcoholic steatohepatitis. The same pathway is co-opted in cancer, where UDP-glucuronate decarboxylase 1 promotes tumor immune evasion by accelerating KMT2D loss in hepatocellular carcinoma. In development, mutations in UGDH cause human developmental disease, underscoring the non-redundant role of this chemistry in growth and patterning. Finally, the pathway is conserved in plants, where a UDP-glucuronic acid:anthocyanin glucuronosyltransferase uses the metabolite for flower pigment biosynthesis, making GO:0006065 a cross-kingdom research topic.
• Supplies UDP-glucuronate, the obligate donor for hepatic glucuronidation and xenobiotic clearance.
• Feeds vitamin C synthesis in species where glucuronate is directly formed from UDP-glucuronate in liver.
• Provides precursors for hyaluronan and glycosaminoglycan production in connective tissue.
• Is dysregulated in nonalcoholic steatohepatitis, where UDP-glucuronate metabolism controls RIPK1-driven liver damage.
• Is co-opted in hepatocellular carcinoma, where UDP-glucuronate decarboxylase 1 promotes immune evasion via KMT2D loss.
• Is linked to human developmental disease through UGDH mutations.
• Supports chondrocyte biology, as UDP-glucuronate carboxy-lyase activity has been characterized in cultured chondrocytes.
• Contributes to plant pigment biosynthesis via glucuronosyltransferase activity.
• Serves as a model for nucleotide sugar coordination between hyaluronan and glycosaminoglycan pathways.
• Offers tractable enzymatic targets for CRISPR functional genomics and metabolic intervention.
What Happens During UDP-glucuronate biosynthetic process?
Step 1: Supply of UDP-glucose precursor
In simple terms: The pathway starts with a sugar nucleotide that the cell already uses for many jobs.
UDP-glucuronate biosynthesis begins from UDP-glucose, a nucleotide sugar generated in the course of liver glucose metabolism. In humans, the liver is a major site of glucose handling, and the pool of UDP-glucose is positioned to feed multiple branches, including the oxidative route that yields UDP-glucuronate. Because UDP-glucose is also used for glycogen and other glycoconjugates, the availability of this precursor is a point of metabolic competition that influences how much UDP-glucuronate is made.
Step 2: Oxidation of UDP-glucose to UDP-glucuronate by UGDH
In simple terms: An enzyme chemically modifies the sugar nucleotide by adding oxygen, turning it into UDP-glucuronate.
The central enzymatic conversion in GO:0006065 is catalyzed by UDP-glucose 6-dehydrogenase (UGDH), which oxidizes UDP-glucose to UDP-glucuronate. This reaction installs the carboxylate group that defines glucuronic acid and creates the glycosidic linkage to uridine diphosphate described in the QuickGO definition. UGDH is the best-characterized enzyme of the pathway, and its loss or mutation has direct consequences for human development. Because the reaction is a committed step, UGDH activity is a common focus for knockout and point-mutation studies.
Step 3: Compartmental use and downstream branching
In simple terms: Once made, UDP-glucuronate is shipped to different reactions that use it for detoxification, vitamin production or structural sugars.
After synthesis, UDP-glucuronate is consumed by several downstream routes. In liver, it can be converted to glucuronate, which is the precursor of vitamin C in species that synthesize ascorbate, as shown by the demonstration that glucuronate is directly formed from UDP-glucuronate in liver. It also serves as a donor for glucuronidation reactions and for glycosaminoglycan assembly, where coordination between hyaluronan and glycosaminoglycan production depends on nucleotide sugar availability. In cultured chondrocytes, UDP-glucuronate carboxy-lyase activity has been characterized, indicating that cartilage cells can further process this metabolite.
Step 4: Decarboxylation and specialized outputs
In simple terms: Some cells trim the molecule further to make other sugars used in signaling and matrix.
UDP-glucuronate decarboxylase enzymes convert UDP-glucuronate toward UDP-xylose and related products, linking GO:0006065 to proteoglycan and signaling biology. In hepatocellular carcinoma, UDP-glucuronate decarboxylase 1 promotes tumor immune evasion by accelerating KMT2D loss, showing that this downstream step can have epigenetic and immunological consequences. In plants, a UDP-glucuronic acid:anthocyanin glucuronosyltransferase uses the metabolite for flower pigment biosynthesis, illustrating the evolutionary breadth of the pathway.
Step 5: Pathway integration with cell death and stress signaling
In simple terms: When the pathway is overloaded, it can trigger stress responses that damage cells.
Recent work shows that UDP-glucuronate metabolism is not merely biosynthetic but can actively control cell fate. In nonalcoholic steatohepatitis, UDP-glucuronate metabolism controls RIPK1-driven liver damage, placing the pathway upstream of a kinase that governs necroptosis and inflammation. This finding reframes GO:0006065 as a stress-responsive process whose flux must be tightly regulated to avoid pathological signaling. It also suggests that measuring UDP-glucuronate levels and UGDH activity can serve as a readout of liver stress in experimental models.
Key Genes Involved in GO:0006065 UDP-glucuronate biosynthetic process
The following genes and enzymes are the principal experimental handles for studying UDP-glucuronate biosynthetic process, spanning synthesis, downstream consumption and disease-associated regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| UGDH | Oxidizes UDP-glucose to UDP-glucuronate, the committed step of GO:0006065 | Mutations cause human developmental disease; prime target for knockout and point-mutation models |
| UGDH (catalytic variants) | Altered dehydrogenase activity and substrate handling | Used to test genotype-phenotype relationships in developmental disease |
| UXS1 / UDP-glucuronate decarboxylase 1 | Converts UDP-glucuronate toward UDP-xylose and related products | Promotes tumor immune evasion via KMT2D loss in hepatocellular carcinoma |
| UGDH in liver | Controls UDP-glucuronate flux in hepatocytes | Linked to RIPK1-driven liver damage in nonalcoholic steatohepatitis |
| Glucuronosyltransferase (plant) | Transfers glucuronic acid from UDP-glucuronic acid to anthocyanin | Model for enzyme evolution and pigment biosynthesis |
| UDP-glucuronate carboxy-lyase | Decarboxylates UDP-glucuronate in chondrocytes | Relevant to cartilage biology and skeletal development |
| HAS enzymes (hyaluronan synthases) | Use nucleotide sugars including UDP-glucuronate for hyaluronan | Studied for matrix production and coordination with glycosaminoglycans |
| GAG biosynthetic enzymes | Consume UDP-glucuronate for glycosaminoglycan chains | Relevant to connective tissue and extracellular matrix research |
| Glucuronidation enzymes (UGTs) | Use UDP-glucuronate as donor for xenobiotic conjugation | Central to drug metabolism and liver function studies |
| Glucose metabolic enzymes | Supply UDP-glucose precursor via liver glucose metabolism | Connect GO:0006065 to systemic glucose handling |
| Ascorbate synthesis enzymes | Convert glucuronate derived from UDP-glucuronate to vitamin C | Species-specific vitamin C biology |
| RIPK1 | Kinase activated downstream of UDP-glucuronate imbalance | Effector of liver damage in NASH models |
| KMT2D | Epigenetic regulator whose loss is accelerated by UXS1 | Tumor immune evasion mechanism in HCC |
| UGDH regulatory partners | Modulate UGDH activity and pathway flux | Candidate modifiers in developmental disease |
| Nucleotide sugar transporters | Move UDP-glucuronate and related sugars across membranes | Control substrate availability for downstream enzymes |
| Chondrocyte metabolic enzymes | Support UDP-glucuronate carboxy-lyase activity | Cartilage and skeletal research |
How Is UDP-glucuronate biosynthetic process Regulated?
UDP-glucuronate biosynthetic process is regulated at the level of precursor supply, enzyme abundance and downstream demand. Because UDP-glucose is a shared metabolite in liver glucose metabolism, the flux into GO:0006065 competes with other glucose-dependent pathways, and the liver is a principal site where this balance is set. UGDH, the committed enzyme, is a focal point of regulation, and its mutations alter pathway output in human developmental disease. Downstream demand from hyaluronan and glycosaminoglycan production also feeds back on nucleotide sugar availability, as mechanisms coordinating these pathways have been described. In disease states, the pathway intersects with stress signaling: UDP-glucuronate metabolism controls RIPK1-driven liver damage in nonalcoholic steatohepatitis, indicating that inflammatory or metabolic stress can rewire pathway activity. In cancer, UXS1-mediated consumption of UDP-glucuronate accelerates KMT2D loss, linking pathway flux to epigenetic regulation and immune evasion.
UDP-glucuronate biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| UGDH | Human developmental disease caused by UGDH mutations | Knockout and point-mutation cell models to test enzyme loss |
| UXS1 | Tumor immune evasion via KMT2D loss in hepatocellular carcinoma | Knockout and overexpression in HCC cell lines |
| UGDH / UDP-glucuronate pathway | RIPK1-driven liver damage in nonalcoholic steatohepatitis | Hepatocyte knockout and metabolite rescue models |
| UDP-glucuronate carboxy-lyase | Chondrocyte biology and cartilage metabolism | Chondrocyte culture with enzyme inhibition |
| Hyaluronan and GAG enzymes | Connective tissue and extracellular matrix disorders | Knock-in reporters of nucleotide sugar flux |
UDP-glucuronate biosynthetic process in nonalcoholic steatohepatitis
Nonalcoholic steatohepatitis is a metabolic liver disease in which hepatocyte stress and inflammation drive injury. Studies show that UDP-glucuronate metabolism controls RIPK1-driven liver damage in this condition, placing GO:0006065 upstream of a key cell-death kinase. This link suggests that measuring UDP-glucuronate levels or UGDH activity could stratify disease severity and that pathway enzymes are candidate therapeutic nodes.
UDP-glucuronate biosynthetic process in hepatocellular carcinoma
In hepatocellular carcinoma, UDP-glucuronate decarboxylase 1 promotes tumor immune evasion by accelerating KMT2D loss. This connects the pathway to epigenetic silencing and to the ability of tumors to escape immune surveillance. The finding supports investigating UXS1 and related enzymes as targets for combination immunotherapy strategies.
UGDH mutations and human developmental disease
Mutations in UGDH, the enzyme that produces UDP-glucuronate, cause human developmental disease. Recent insights into these mutations have clarified how loss of pathway flux affects growth and patterning. This makes UGDH a paradigm for connecting a nucleotide sugar biosynthetic step to organism-level phenotypes.
UDP-glucuronate biosynthetic process in connective tissue and cartilage
UDP-glucuronate is a precursor for hyaluronan and glycosaminoglycans, and mechanisms coordinating their production have been described. In cultured chondrocytes, UDP-glucuronate carboxy-lyase activity has been characterized, linking the pathway to cartilage metabolism. These findings are relevant to skeletal disorders and matrix biology.
From UDP-glucuronate biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of UGDH abolish UDP-glucuronate production? | UGDH knockout cell line with metabolite profiling |
| Which UGDH missense variants impair enzyme function? | Point-mutation knock-in of patient variants |
| Does UXS1 drive immune evasion in HCC? | UXS1 knockout and overexpression in hepatocellular carcinoma cells |
| Can UDP-glucuronate flux be monitored in live cells? | Tagged knock-in of pathway enzymes or reporters |
| Does UDP-glucuronate accumulation trigger RIPK1 signaling? | Hepatocyte models with pathway perturbation and RIPK1 readouts |
| How does pathway flux affect glycosaminoglycan output? | Overexpression of biosynthetic enzymes in matrix-producing cells |
How to Study the UDP-glucuronate biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS nucleotide sugar profiling | Levels of UDP-glucuronate and related metabolites | Validating pathway flux after CRISPR perturbation |
| UGDH enzyme assay | Conversion of UDP-glucose to UDP-glucuronate | Testing patient variants and inhibitors |
| CRISPR knockout screening | Gene requirement for pathway output | Identifying modifiers of immune evasion |
| RNA sequencing | Transcriptional consequences of pathway perturbation | Mapping stress and immune programs |
| Proteomics | Protein abundance and modification changes | Linking pathway flux to epigenetic regulators |
| Glucuronosyltransferase assay | Transfer of glucuronic acid to acceptors | Plant pigment and enzyme evolution studies |
| Chondrocyte carboxy-lyase assay | Decarboxylation of UDP-glucuronate | Cartilage metabolism research |
| Metabolic flux analysis | Coordination of hyaluronan and GAG production | Matrix biology and tissue engineering |
Metabolite profiling of nucleotide sugars
Because GO:0006065 is defined by the formation of UDP-glucuronate, direct measurement of nucleotide sugars is a primary method. Liquid chromatography-mass spectrometry can quantify UDP-glucuronate and its precursors in cell extracts, allowing researchers to test whether genetic perturbations alter pathway flux. Such profiling is essential for validating knockout and overexpression models.
Enzyme activity assays for UGDH and downstream enzymes
UGDH activity can be measured by monitoring the conversion of UDP-glucose to UDP-glucuronate in vitro. Similar assays exist for UDP-glucuronate decarboxylase and glucuronosyltransferases, enabling functional classification of variants. These assays are often paired with recombinant enzyme expression to isolate catalytic effects.
CRISPR-based functional genomics
CRISPR knockout, point-mutation and knock-in approaches allow causal testing of pathway genes in relevant cell types. Pooled screens can identify modifiers of UDP-glucuronate levels or downstream phenotypes such as immune evasion. These methods are now standard for dissecting GO:0006065 in disease models.
Transcriptomic and proteomic readouts
RNA sequencing and proteomics can reveal how pathway perturbation reshapes gene expression and protein abundance, including stress and immune programs. In hepatocellular carcinoma, such readouts helped link UXS1 to KMT2D loss and immune evasion. In liver disease models, they connect UDP-glucuronate metabolism to RIPK1 signaling.
How CRISPR Can Be Used to Study GO:0006065 UDP-glucuronate biosynthetic process
Knockout
CRISPR knockout of UGDH or UXS1 is used to eliminate pathway flux and test downstream consequences, such as loss of UDP-glucuronate production or altered immune evasion. Knockout models are also valuable for confirming that observed phenotypes depend on the enzymatic step rather than on off-target effects. In liver disease research, knockout of pathway genes can test whether UDP-glucuronate metabolism is required for RIPK1-driven damage.
Point Mutation
Point-mutation knock-in allows researchers to model patient-specific UGDH variants and distinguish loss-of-function from hypomorphic alleles. This approach is particularly useful when complete knockout is lethal or when subtle catalytic changes are suspected. Point mutants can be paired with enzyme assays to correlate genotype with residual activity.
Knock-in
Knock-in of tags or reporters into pathway genes enables real-time monitoring of enzyme localization and metabolite flux. Tagged knock-in lines can also be used to immunoprecipitate pathway complexes and identify regulatory partners. This strategy supports mechanistic studies of how UDP-glucuronate biosynthesis is coordinated with downstream glycosaminoglycan production.
Overexpression
Overexpression of UGDH, UXS1 or downstream enzymes can amplify pathway flux and reveal gain-of-function phenotypes, such as enhanced immune evasion in hepatocellular carcinoma. Overexpression models are also used to test whether increased UDP-glucuronate supply is sufficient to drive matrix or pigment outputs. These systems complement knockout studies by probing the upper limits of pathway activity.
How EDITGENE Supports UDP-glucuronate biosynthetic process Research
Researchers studying UDP-glucuronate biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in metabolite production, stress signaling or disease phenotypes. EDITGENE provides the CRISPR cell models and screening services required to move from correlation to causation in this pathway.
Contact EDITGENE today to design your custom CRISPR model for UDP-glucuronate biosynthetic process research.
Frequently Asked Questions About UDP-glucuronate biosynthetic process
What is UDP-glucuronate biosynthetic process?
It is the biological process, annotated as GO:0006065, that produces UDP-glucuronate, a nucleotide sugar composed of glucuronic acid linked to uridine diphosphate.
What genes are involved in UDP-glucuronate biosynthetic process?
Key genes include UGDH, which makes UDP-glucuronate, and UXS1, which consumes it; downstream enzymes such as glucuronosyltransferases and hyaluronan synthases also participate.
What does GO:0006065 mean?
GO:0006065 is the Gene Ontology identifier for UDP-glucuronate biosynthetic process, a biological process term describing the reactions that form UDP-glucuronate.
Why is UDP-glucuronate important in the liver?
The liver is a major site of glucose metabolism and uses UDP-glucuronate for glucuronidation and other pathways; its dysregulation is linked to RIPK1-driven liver damage in nonalcoholic steatohepatitis.
How is UDP-glucuronate made?
UGDH oxidizes UDP-glucose to UDP-glucuronate, the committed step of the pathway.
Is UDP-glucuronate involved in cancer?
Yes, UDP-glucuronate decarboxylase 1 promotes tumor immune evasion by accelerating KMT2D loss in hepatocellular carcinoma.
What diseases are linked to UGDH mutations?
UGDH mutations cause human developmental disease, and recent insights have clarified their clinical and biochemical impact.
How do researchers study UDP-glucuronate biosynthetic process?
They use metabolite profiling, enzyme assays, CRISPR knockout and point-mutation models, and transcriptomic or proteomic readouts.
Can CRISPR be used to study GO:0006065?
Yes, CRISPR knockout, point-mutation, knock-in and overexpression models are widely used to test causal roles of pathway genes.
What is the relationship between UDP-glucuronate and glycosaminoglycans?
UDP-glucuronate is a precursor for hyaluronan and glycosaminoglycan production, and mechanisms coordinating these pathways have been described.
Conclusion
UDP-glucuronate biosynthetic process (GO:0006065) is a compact but consequential metabolic pathway that supplies a nucleotide sugar used in detoxification, vitamin synthesis, matrix assembly and cell-fate signaling. Its enzymes, especially UGDH and UXS1, are directly implicated in human developmental disease, nonalcoholic steatohepatitis and hepatocellular carcinoma. Because the pathway is enzymatically tractable and conserved across kingdoms, it is well suited to CRISPR-based functional genomics. Researchers who combine precise genetic models with metabolite and transcriptome profiling can define how this pathway contributes to health and disease.
References
- 1. Adeva-Andany MM et al.. 2016. Liver glucose metabolism in humans.. Biosci Rep 36(6) PMID: 27707936
- 2. Zhang T et al.. 2023. UDP-glucuronate metabolism controls RIPK1-driven liver damage in nonalcoholic steatohepatitis.. Nat Commun 14(1):2715 PMID: 37169760
- 3. Zhang J et al.. 2026. UDP-glucuronate decarboxylase 1 promotes tumor immune evasion by accelerating KMT2D loss in hepatocellular carcinoma.. J Immunother Cancer 14(7) PMID: 42419879
- 4. Sawada S et al.. 2005. UDP-glucuronic acid:anthocyanin glucuronosyltransferase from red daisy (Bellis perennis) flowers. Enzymology and phylogenetics of a novel glucuronosyltransferase involved in flower pigment biosynthesis.. J Biol Chem 280(2):899-906 PMID: 15509561
- 5. Linster CL et al.. 2006. Glucuronate, the precursor of vitamin C, is directly formed from UDP-glucuronate in liver.. FEBS J 273(7):1516-27 PMID: 16689937
- 6. John KV et al.. 1977. UDP-glucuronate carboxy-lyase in cultured chondrocytes.. J Biol Chem 252(19):6707-10 PMID: 197101
- 7. Harwood H et al.. 2025. Recent insights into the implications of UGDH mutations for human developmental disease.. Biochem Soc Trans 53(4):1119-1128 PMID: 40879729
- 8. Zimmer BM et al.. 2022. Mechanisms of coordinating hyaluronan and glycosaminoglycan production by nucleotide sugars.. Am J Physiol Cell Physiol 322(6):C1201-C1213 PMID: 35442826
